Genome-Free SARS-CoV-2 VLPs for Rapid Variant Entry Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating SARS-CoV-2 variants and mutants are inefficient and limited by biosafety level 3 handling requirements, hindering the development of effective treatments and vaccines.
Innovation Solution
Development of SARS-CoV-2 virus-like particles (SC2-VLPs) that include viral structural proteins and a packaging signal-containing messenger RNA, enabling rapid testing of viral structural gene variants for infection efficiency and antibody neutralization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If SARS-CoV-2 variants are evaluated using conventional methods with live virus, then accurate measurement of viral fitness and entry efficiency is achieved, but biosafety level 3 handling requirements and complex procedures are imposed
Solution Approach 1:
The patent creates virus-like particles (VLPs) that are copies of the SARS-CoV-2 virus structure but lack the viral genome, eliminating the need for BSL-3 handling while preserving the ability to evaluate viral entry efficiency and antibody neutralization. The VLPs replicate the viral envelope, spike protein, and overall morphology without containing infectious genetic material.
Solution Approach 2:
The patent extracts the viral genome from the complete virus structure, isolating only the structural components (envelope, membrane, nucleocapsid, and spike proteins) needed for entry evaluation. This extraction removes the biosafety hazard while retaining the functional elements required for measuring viral fitness and antibody neutralization.
2Loss of information
If live SARS-CoV-2 virus is used for variant evaluation, then comprehensive viral behavior data is obtained, but time-consuming and resource-intensive procedures are required
Solution Approach 1:
The VLP system provides a simplified copy that retains the essential entry and neutralization behaviors needed for variant evaluation, eliminating the time-consuming aspects of live virus cultivation and handling while preserving the critical data on viral fitness and antibody responses.
Solution Approach 2:
The evaluation process is segmented into discrete components: VLP production from variant genes, standardized entry assays using recipient cells, and quantitative measurement of neutralization. This segmentation allows for rapid, modular testing of multiple variants without the complex procedures required for live virus work.
3Reliability
If conventional viral assembly methods are used, then authentic viral structures are produced, but scalability and manufacturing efficiency are limited
Solution Approach 1:
The VLP production system creates authentic viral structures through controlled expression of structural proteins in cultured cells, followed by purification. This copying approach maintains structural fidelity while enabling scalable manufacturing that is not constrained by the limitations of live virus propagation.
Solution Approach 2:
The patent replaces the complex biological system of live virus replication with a controlled protein expression and self-assembly system. Structural proteins are expressed in cultured cells, purified, and spontaneously assemble into VLPs under controlled conditions, enabling scalable production while maintaining structural authenticity.
Data Source
AI summary
Provided herein are SARS-CoV-2 virus-like particles as well as methods and compositions for generating SARS-CoV-2 virus-like particles. The SARS-CoV-2 virus-like particles can load and deliver transcripts (including engineered transcripts that can include therapeutic agents) into cells expressing SARS-CoV-2 entry factors. The SARS-CoV-2 virus-like particles are also useful for detecting immune response in antibodies from subjects.